Tiny Sensors That Catch Cancer Cells in the Blood Are Racing Toward the Clinic

A single tube of blood may soon tell oncologists more about a patient’s tumor than a surgical biopsy ever could. Circulating tumor cells, or CTCs, and circulating tumor DNA, known as ctDNA, are shed into the bloodstream by tumors and can reveal how the disease is evolving in real time. But these molecular messengers are extraordinarily scarce, often appearing at concentrations of a handful of cells or a few mutated DNA fragments among billions of healthy counterparts. A comprehensive review published in the Annals of Biomedical Engineering by Tuğba Ören Varol and Mehmet Varol of Mugla Sitki Kocman University maps out how electrochemical biosensors, devices that translate biological recognition into electrical signals, are emerging as the most practical path to detecting these elusive biomarkers outside of specialized laboratories.

The appeal of electrochemical detection lies in its fundamental physics. Rather than relying on bulky optics or fluorescence microscopy, these sensors measure currents, voltages, or impedance changes at an electrode surface when a target molecule binds to a recognition element immobilized there. Amperometric readouts track the flow of electrons generated by redox reactions, potentiometric schemes register voltage shifts at equilibrium, and impedance-based approaches detect how a captured cell or DNA strand alters the electrical resistance at the interface. The result is instrumentation that can be miniaturized to the size of a credit card, manufactured at low cost, and operated by a smartphone, exactly the profile needed for point-of-care testing in clinics and, eventually, at home.

One of the most consequential insights highlighted in the review concerns a biological blind spot in conventional CTC capture. Most commercial platforms rely on antibodies against EpCAM, an epithelial cell surface protein abundant on many tumor cells. Yet tumors do not stand still. During epithelial–mesenchymal transition, or EMT, cancer cells suppress epithelial markers like EpCAM and adopt mesenchymal traits that make them more motile, more invasive, and far more likely to seed metastases. The very cells that matter most for prognosis are the ones that EpCAM-based systems miss. The review emphasizes next-generation sensing strategies specifically designed to catch EMT-associated phenotypes, using panels of aptamers and antibodies directed at mesenchymal and stem cell markers, deformability-based microfluidic separation, and dual-recognition schemes that require multiple binding events to confirm a cell’s identity.

Behind every successful biosensor stands a carefully engineered electrode surface. Nanomaterials have transformed this field by multiplying the effective area available for molecular recognition and by accelerating electron transfer. Gold nanoparticles, graphene and its derivatives, carbon nanotubes, MXenes, and metal–organic frameworks have all been deployed to decorate electrodes with conductive, high-surface-area architectures. Three-dimensional printed graphene-coated electrodes have pushed detection limits toward the single-molecule regime, while silicon nanowire arrays have achieved supersensitive quantification of ctDNA. Conducting polymers add another layer of control, allowing researchers to build biocompatible, antifouling films that keep blood proteins from swamping the signal.

Molecular recognition itself is undergoing a quiet revolution. Antibodies remain workhorses, but aptamers, short synthetic strands of DNA or RNA selected through systematic evolution of ligands by exponential enrichment, offer chemical stability, easy modification, and the ability to bind targets as diverse as whole cells, proteins, and specific mutation-bearing DNA sequences. DNA frameworks and nanostructures can now present aptamers in engineered arrays that remain stable in flowing blood, dramatically improving capture efficiency for heterogeneous CTC populations. The review also surveys dual-aptamer and antibody-aptamer combinations that crosslink target cells to electrode surfaces with far greater specificity than any single binder could achieve.

Scarcity of target demands signal amplification, and the review devotes detailed attention to the molecular machines that provide it. Rolling circle amplification uses a circular DNA template and a strand-displacing polymerase to generate long, repetitive products that carry hundreds of detectable tags. Terminal deoxynucleotidyl transferase-mediated polymerization extends probe strands with long tails of signaling molecules. Perhaps most striking are DNA nanomachines, including bipedal and multipedal DNA walkers that traverse electrode surfaces, catalytically cleaving or assembling reporter strands as they go, converting a single binding event into a cascade of electrochemical signals. Coupled with hybridization chain reactions and catalytic hairpin assembly, these enzyme-free cascades can push limits of detection into the attomolar range without any thermal cycling equipment.

Integration with microfluidics is what turns these chemistries into usable devices. Chips that generate microvortices, spiral channels that sort cells by deformability, and hydrodynamic plasma separators can process milliliters of whole blood in minutes, concentrating targets before they reach the sensing electrode. The review describes electromicrofluidic devices in which captured cells can be gently released under controlled chemical conditions, enabling downstream culture and molecular analysis rather than destructive detection alone. Some platforms now measure PD-L1 expression on captured CTCs without reagents, offering a window into whether a patient is likely to respond to immune checkpoint inhibitors, a decision that traditionally requires tissue that may be inaccessible.

The digital layer is where the field is accelerating fastest. Smartphone-based potentiostats have already demonstrated clinical-grade microRNA and biomarker detection with cloud connectivity, while internet-of-things-enabled embedded potentiostats stream electrochemical data directly to remote servers. Artificial intelligence is being applied at every level, from deep learning models that identify CTCs in complex backgrounds to machine learning classifiers that read ion current fingerprints of individual cells. The review highlights federated learning as a particularly promising framework, allowing algorithms to be trained across multiple hospitals without patient data ever leaving the institution, addressing both the statistical hunger of AI models and the privacy constraints of clinical medicine.

None of this means the technology is ready for prime time without confronting hard problems. Sensor fouling by serum proteins, interference from the staggeringly complex matrix of whole blood, batch-to-batch variability in electrode fabrication, and the dearth of large-scale clinical validation studies all stand between impressive prototypes and regulatory approval. Antifouling surface chemistries, ratiometric electrochemical methods that reference signals internally to improve reproducibility, and ISO-compliant standardization frameworks are among the emerging solutions the authors outline. The translational history of point-of-care biosensing in other diseases suggests these hurdles are surmountable, but they demand sustained collaboration between engineers, clinicians, and regulators.

What emerges from this synthesis is a picture of a field approaching an inflection point. The individual components, nanomaterial-enhanced electrodes, smart aptamers, enzymatic and DNA-based amplification, microfluidic sample preparation, and AI-driven analytics, have each matured considerably. The remaining challenge, and the central thesis of the review, is architectural: weaving them into integrated, validated, sample-to-answer systems that can monitor CTCs and ctDNA continuously, affordably, and accurately. If that integration succeeds, the era in which cancer is tracked through a routine blood draw, with treatment adjusted as the tumor’s molecular signature shifts, moves from promise to practice.

Subject of Research: Electrochemical biosensors for detecting circulating tumor cells and circulating tumor DNA in liquid biopsy

Article Title: Electrochemical Biosensors for Circulating Tumor Cells and ctDNA: Emerging Strategies for Precision Oncology

Article References: Electrochemical Biosensors for Circulating Tumor Cells and ctDNA: Emerging Strategies for Precision Oncology. (n.d.). https://doi.org/10.1007/s10439-026-04396-z

Image Credits: AI Generated

DOI: 10.1007/s10439-026-04396-z

Keywords: electrochemical biosensors, circulating tumor cells, ctDNA, liquid biopsy, precision oncology, aptamers, nanomaterials, DNA nanomachines, microfluidics, point-of-care testing, EMT, artificial intelligence